1
|
Thoraval L, Thiébault E, Siboni R, Moniot A, Guillaume C, Jacobs A, Nedelec JM, Renaudin G, Descamps S, Valfort O, Gangloff S, Braux J, Marchat D, Velard F. The acute inflammatory response to copper(II)-doped biphasic calcium phosphates. Mater Today Bio 2023; 23:100814. [PMID: 37841800 PMCID: PMC10568289 DOI: 10.1016/j.mtbio.2023.100814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 09/05/2023] [Accepted: 09/22/2023] [Indexed: 10/17/2023] Open
Abstract
Infection and inflammation are two key features to consider to avoid septic or aseptic loosening of bone-implanted biomaterials. In this context, various approaches to fine-tune the biomaterial's properties have been studied in order to modulate the crosstalk between immune and skeletal cells. Cation-doping strategies for tuning of calcium phosphates properties has been evidenced as a promising way to control the biomaterial-induced inflammatory process, and thus improving their osteoimmunomodulatory properties. Copper(II) ions are recognized for their antibacterial potential, but the literature on their impact on particulate material-induced acute inflammation is scarce. We synthesized copper(II) ions-doped biphasic calcium phosphate (BCP), intended to exhibit osteoimmunomodulatory properties. We addressed in vitro, for the first time, the inflammatory response of human primary polymorphonuclear neutrophils (PMNs) to copper(II) ions-doped or undoped (BCP) powders, synthesized by an original and robust wet method, in the presence or absence of LPS as a costimulant to mimic an infectious environment. ELISA and zymography allowed us to evidence, in vitro, a specific increase in IL-8 and GRO-α secretion but not MIP-1β, TNF-α, or MMP-9, by PMNs. To assess in vivo relevance of these findings, we used a mouse air pouch model. Thanks to flow cytometry analysis, we highlighted an increased PMN recruitment with the copper(II) ions-doped samples compared to undoped samples. The immunomodulatory effect of copper(II) ions-doped BCP powders and the consequent induced moderate level of inflammation may promote bacterial clearance by PMNs in addition to the antimicrobial potential of the material. Copper(II) doping provides new insights into calcium phosphate (CaP)-based biomaterials for prosthesis coating or bone reconstruction by effectively modulating the inflammatory environment.
Collapse
Affiliation(s)
- L. Thoraval
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - E. Thiébault
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - R. Siboni
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - A. Moniot
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - C. Guillaume
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - A. Jacobs
- Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, Clermont-Ferrand, France
| | - J.-M. Nedelec
- Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, Clermont-Ferrand, France
| | - G. Renaudin
- Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, Clermont-Ferrand, France
| | - S. Descamps
- Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, Clermont-Ferrand, France
| | - O. Valfort
- Mines Saint-Etienne, Univ Lyon, CNRS, UMR 5307 LGF, Centre SPIN, F-42023, Saint-Etienne, France
| | - S.C. Gangloff
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - J. Braux
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| | - D. Marchat
- Mines Saint-Etienne, Univ Jean Monnet, Etablissement Français du Sang, INSERM, U 1059 Sainbiose, 42023, Saint-Etienne, France
| | - F. Velard
- Université de Reims Champagne-Ardenne, EA4691 “Biomatériaux et Inflammation en site osseux” BIOS, Reims, France
| |
Collapse
|
2
|
Testelmans D, Papadopoulos D, Kalkanis A, Jacobs A, Van Hende F, Vandebotermet M, Belge C, Buyse B. Telemonitoring-guided ambulatory fixed CPAP titration versus ambulatory APAP titration in moderate obstructive sleep apnea: A non-inferiority randomized controlled trial. J Sleep Res 2023; 32:e13887. [PMID: 36944532 DOI: 10.1111/jsr.13887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/26/2023] [Accepted: 02/28/2023] [Indexed: 03/23/2023]
Abstract
The present study aimed to evaluate whether titration of fixed continuous positive airway pressure at home using telemonitoring produces patient outcomes equal to auto-adjusting positive airway pressure titration at home for patients with moderate obstructive sleep apnea. Patients were randomized with a 1:1 allocation ratio to receive either auto-adjusting positive airway pressure titration based on the median of the 95th percentile pressure across seven nights or fixed continuous positive airway pressure titration based on a fixed calculated pressure and specific adaptations after telemonitoring of device data after 3 and 7 nights. The results of the ambulatory titration were evaluated with in-laboratory polysomnography after 2 weeks. We hypothesized that fixed continuous positive airway pressure titration would be non-inferior to auto-adjusting positive airway pressure titration in respect to continuous positive airway pressure adherence at a 3-month follow-up. A non-inferiority margin of -0.75 hr was prespecified. One-hundred and four patients were randomly allocated to fixed continuous positive airway pressure (n = 52) and auto-adjusting positive airway pressure (n = 52) titration. The mean difference and the 95% confidence intervals in continuous positive airway pressure adherence after 3 months between the two arms were 0.80 (-0.08, 1.69) hr. The non-inferiority hypothesis was confirmed as the lower one-sided 97.5% confidence interval for the mean difference was above the prespecified margin. Patients in the fixed continuous positive airway pressure titration arm were titrated at significantly lower pressure level and had a significantly lower amount of average leaks compared with auto-adjusting positive airway pressure-titrated patients, while there was no difference in residual obstructive apnea-hypopnea index on polysomnography. Telemonitoring enables ambulatory continuous positive airway pressure titration with fixed pressure that is non-inferior to ambulatory titration with auto-adjusting pressure in patients with moderate obstructive sleep apnea.
Collapse
Affiliation(s)
- D Testelmans
- Department of Pneumology, University Hospitals Leuven, Leuven, Belgium
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
| | - D Papadopoulos
- Department of Pneumology, University Hospitals Leuven, Leuven, Belgium
| | - A Kalkanis
- Department of Pneumology, University Hospitals Leuven, Leuven, Belgium
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
| | - A Jacobs
- Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
| | - F Van Hende
- Department of Pneumology, AZ St-Dimpna, Geel, Belgium
| | | | - C Belge
- Department of Pneumology, University Hospitals Leuven, Leuven, Belgium
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
| | - B Buyse
- Department of Pneumology, University Hospitals Leuven, Leuven, Belgium
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
| |
Collapse
|
3
|
Degenaar A, Jacobs A, Kruger R, Delles C, Mischak H, Mels C. Cardiovascular risk and kidney function profiling using conventional and novel biomarkers in young adults: the African-PREDICT study. BMC Nephrol 2023; 24:96. [PMID: 37055746 PMCID: PMC10103421 DOI: 10.1186/s12882-023-03100-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 03/02/2023] [Indexed: 04/15/2023] Open
Abstract
BACKGROUND Low- and middle-income countries experience an increasing burden of chronic kidney disease. Cardiovascular risk factors, including advancing age, may contribute to this phenomenon. We (i) profiled cardiovascular risk factors and different biomarkers of subclinical kidney function and (ii) investigated the relationship between these variables. METHODS We cross-sectionally analysed 956 apparently healthy adults between 20 and 30 years of age. Cardiovascular risk factors such as high adiposity, blood pressure, glucose levels, adverse lipid profiles and lifestyle factors were measured. Various biomarkers were used to assess subclinical kidney function, including estimated glomerular filtration rate (eGFR), urinary albumin, uromodulin and the CKD273 urinary proteomics classifier. These biomarkers were used to divide the total population into quartiles to compare extremes (25th percentiles) on the normal kidney function continuum. The lower 25th percentiles of eGFR and uromodulin and the upper 25th percentiles of urinary albumin and the CKD273 classifier represented the more unfavourable kidney function groups. RESULTS In the lower 25th percentiles of eGFR and uromodulin and the upper 25th percentile of the CKD273 classifier, more adverse cardiovascular profiles were observed. In multi-variable adjusted regression analyses performed in the total group, eGFR associated negatively with HDL-C (β= -0.44; p < 0.001) and GGT (β= -0.24; p < 0.001), while the CKD273 classifier associated positively with age and these same risk factors (age: β = 0.10; p = 0.021, HDL-C: β = 0.23; p < 0.001, GGT: β = 0.14; p = 0.002). CONCLUSION Age, lifestyle and health measures impact kidney health even in the third decade.
Collapse
Affiliation(s)
- A Degenaar
- Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa
| | - A Jacobs
- Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa
- MRC Research Unit: Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa
| | - R Kruger
- Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa
- MRC Research Unit: Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa
| | - C Delles
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
| | - H Mischak
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
- Mosaiques Diagnostics GmbH, Hannover, Germany
| | - Cmc Mels
- Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa.
- MRC Research Unit: Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa.
| |
Collapse
|
4
|
Moseson H, Wollum A, Goode BA, Campos A, Key K, Bommaraju A, Jeyifo M, Shariyf Q, Stern MS, Jacobs A, Smith E, Dreyfus-Pai PN, Dockray P. P016Experiences of self-managed abortion in indiana: Financial barriers to clinical care and a need for information on self-managed medication abortion. Contraception 2022. [DOI: 10.1016/j.contraception.2022.09.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Abstract
Reconstruction plays a valuable role in the management of lower extremity wounds for limb salvage. The goals of reconstruction are to improve function and quality of life, return to work, and pain reduction while providing a long-lasting durable reconstruction. The plastics and reconstructive surgical approach in conjunction with the orthopedic or trauma team, referred often as the "orthoplastic" approach, can yield the best outcomes for patients. The following sections discuss reconstruction principles and techniques that can be applied broadly for lower extremity wounds secondary to trauma, infection, and tumor resection.
Collapse
Affiliation(s)
- Ahmed M Mansour
- Division of Plastic and Reconstructive Surgery, Lehigh Valley Health Network, 1250 South Cedar Crest Boulevard, Allentown, PA 18103, USA.
| | - Aaron Jacobs
- Division of Plastic and Reconstructive Surgery, Lehigh Valley Health Network, 1250 South Cedar Crest Boulevard, Allentown, PA 18103, USA
| | - Mamtha S Raj
- Division of Plastic and Reconstructive Surgery, Lehigh Valley Health Network, 1250 South Cedar Crest Boulevard, Allentown, PA 18103, USA
| | - Frank G Lee
- University of South Florida Morsani College of Medicine, 2049 Street Wood Street, Allentown, PA 18103, USA
| | - Weston Terrasse
- Division of Plastic and Reconstructive Surgery, Lehigh Valley Health Network, 1250 South Cedar Crest Boulevard, Allentown, PA 18103, USA
| | - Sean J Wallace
- Division of Plastic and Reconstructive Surgery, Lehigh Valley Health Network, 3701 Corriere Road, Suite 15, Easton, PA 18045, USA
| | - Nathan F Miller
- Division of Plastic and Reconstructive Surgery, Lehigh Valley Health Network, 1250 South Cedar Crest Boulevard, Allentown, PA 18103, USA
| |
Collapse
|
6
|
Nijland L, Reiber B, Monpellier V, Jacobs A, Hazebroek E, van Veen R, Demirkiran A, de Castro S, Liem R, Swank D, Knook M, van Acker G, Tseng L, Marsman H, van Tets W, Cense H, Greve JW, Boerma EJ, Fransen S, de Witte E, Wiezer RM, Wijffels N, te Riele W, Derksen W, Takkenberg M, Aufenacker T, Vening W, Witteman B, den Hengst W. The association between patient attendance to a perioperative group-based lifestyle program and weight loss after bariatric surgery. Surg Obes Relat Dis 2022; 18:747-754. [DOI: 10.1016/j.soard.2022.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 01/23/2022] [Accepted: 02/13/2022] [Indexed: 12/31/2022]
|
7
|
Ledermann JA, Zurawski B, Raspagliesi F, De Giorgi U, Arranz Arija J, Romeo Marin M, Lisyanskaya A, Póka RL, Markowska J, Cebotaru C, Casado Herraez A, Colombo N, Kutarska E, Hall M, Jacobs A, Ahrens-Fath I, Baumeister H, Zurlo A, Sehouli J. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open 2021; 7:100311. [PMID: 34920291 PMCID: PMC8685985 DOI: 10.1016/j.esmoop.2021.100311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 10/13/2021] [Accepted: 10/27/2021] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to evaluate the efficacy and safety of switch maintenance therapy with gatipotuzumab in patients with TA-MUC1-positive recurrent ovarian, fallopian tube, or primary high-grade serous peritoneal cancer. PATIENTS AND METHODS In this double-blind, randomized, placebo-controlled, phase II trial, patients with at least stable disease (SD) following chemotherapy were randomized 2:1 to receive intravenous gatipotuzumab (500 mg followed by 1700 mg 1 week later) or placebo every 3 weeks until tumor progression or unacceptable toxicity occurred. Stratification factors were the number of prior chemotherapy lines (2 versus 3-5), response versus SD after the most recent chemotherapy, and progression-free survival (PFS) <6 versus 6-12 months following the prior therapy. Primary endpoint was PFS according to modified immune-related RECIST 1.1 response criteria. Secondary endpoints were PFS at 6 months, safety, overall response rate, CA-125 progression, overall survival, quality of life, and pharmacokinetics. RESULTS Overall, 216 patients were randomized to gatipotuzumab (n = 151) or placebo (n = 65). Median PFS with gatipotuzumab was 3.5 months as compared with 3.5 months with placebo (hazard ratio 0.96, 95% confidence interval 0.69-1.33, P = 0.80). No advantage for gatipotuzumab over placebo was seen in the secondary efficacy endpoints or in any stratified subgroups. Gatipotuzumab was well tolerated, with mild to moderate infusion-related reactions being the most common adverse events. CONCLUSIONS Gatipotuzumab switch maintenance therapy does not improve outcome in TA-MUC1-positive ovarian cancer patients. TRIAL REGISTRATION ClinicalTrials.govNCT01899599; https://clinicaltrials.gov/ct2/show/NCT01899599.
Collapse
Affiliation(s)
- J A Ledermann
- Department of Oncology, UCL Cancer Institute, University College London, London, UK.
| | - B Zurawski
- Department of Oncology, Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland
| | - F Raspagliesi
- Department of Gynecologic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - U De Giorgi
- Department of Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
| | - J Arranz Arija
- Department of Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain
| | - M Romeo Marin
- Department of Medical Oncology, B-ARGO group, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - A Lisyanskaya
- Department of Oncogynecology, St.-Petersburg Oncological City Hospital, St. Petersburg, Russia
| | - R L Póka
- Department of Gynecologic Oncology, Debrecen University Clinical Center, Debrecen, Hungary
| | - J Markowska
- Klinika Onkologii, Oddzial Ginekologii Onkologicznej, Poznan, Poland
| | - C Cebotaru
- Radioterapie, Institutul Oncologic "Prof. Dr. Ioan Chiricuta", Cluj-Napoca, Romania
| | - A Casado Herraez
- Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - N Colombo
- Department of Medical Gynecologic Oncology, European Institute of Oncology IRCCS, and University of Milano-Bicocca, Milan, Italy
| | - E Kutarska
- Iii Oddzial Ginekologii Onkologicznej, Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland
| | - M Hall
- Mount Vernon Cancer Centre, Middlesex, UK
| | | | | | | | - A Zurlo
- Glycotope GmbH, Berlin, Germany
| | - J Sehouli
- Department of Gynecology and Gynecologic Oncology, Charité Campus Virchow-Klinikum, Berlin, Germany
| |
Collapse
|
8
|
Klinghammer K, Fayette J, Kawecki A, Dietz A, Schafhausen P, Folprecht G, Rottey S, Debourdeau P, Lavernia J, Jacobs A, Ahrens-Fath I, Dietrich B, Baumeister H, Zurlo A, Ochsenreither S, Keilholz U. A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study. ESMO Open 2021; 6:100242. [PMID: 34482179 PMCID: PMC8424211 DOI: 10.1016/j.esmoop.2021.100242] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 07/01/2021] [Accepted: 07/22/2021] [Indexed: 02/05/2023] Open
Abstract
Background The aim of the RESGEX study was to compare the efficacy and safety of the anti-epidermal growth factor receptor (anti-EGFR) antibody tomuzotuximab against cetuximab both in combination with chemotherapy in patients with recurrent and/or metastatic squamous cell cancer of the head and neck in the first-line treatment. Patients and methods In this phase II trial 240 patients were equally randomized for six cycles to receive either tomuzotuximab (initial dose 990 mg then 720 mg) weekly and cisplatin 100 mg/m2 and fluorouracil (5-FU; 1000 mg/m2/day, days 1-4) every 3 weeks or cetuximab (400 mg/m2 subsequent 250 mg/m2) weekly with the same chemotherapeutic backbone followed by antibody maintenance treatment. The primary endpoint was progression-free survival. Results Median progression-free survival was 6.5 months [95% confidence interval (CI) 5.9-7.9 months] in the tomuzotuximab group and 6.2 months (95% CI 5.8-7.3 months) in the cetuximab group (P = 0.86). The median overall survival (OS) estimate was 11.6 months (95% CI 9.5-17.2 months) in the tomuzotuximab group and 13.8 months (95% CI 12.3-16.4 months) in the cetuximab group (P = 0.96). In an exploratory analysis a small subgroup of p16-positive patients had a significantly longer OS compared with p16-negative patients (hazard ratio 1.860, 95% CI 1.09-3.16, P = 0.02). Conclusions The glyco-engineered antibody tomuzotuximab failed to demonstrate improved efficacy with a chemotherapeutic backbone in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. It remains a so far unanswered question whether such antibody would partner better with different drugs such as checkpoint inhibitors. Tomuzotuximab has a potential higher antibody-dependent cell cytotoxicity than other EGFR-directed antibodies. Comparison of two anti-EGFR antibodies combined with chemotherapy in patients with squamous cell cancer of head and neck. Efficacy, safety, and tolerability of tomuzotuximab and cetuximab in combination with chemotherapy were similar.
Collapse
Affiliation(s)
- K Klinghammer
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin Charité - Universitätsmedizin Berlin, Berlin, Germany; Charité Comprehensive Cancer Center, Berlin, Germany.
| | - J Fayette
- Medical Oncology, Centre Léon Bérard, Lyon, France
| | - A Kawecki
- Cancer Center-Maria Sklodowska-Curie Memorial Institute, Warsaw, Poland
| | - A Dietz
- University of Leipzig, Leipzig, Germany; Outpatient Chemotherapy, University of Leipzig, Leipzig, Germany
| | - P Schafhausen
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - G Folprecht
- University Hospital Carl Gustav Carus, Dresden, Germany
| | - S Rottey
- Ghent University Hospital, Department of Medical Oncology, Ghent, Belgium
| | | | | | | | | | | | | | - A Zurlo
- Glycotope GmbH, Berlin, Germany
| | - S Ochsenreither
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin Charité - Universitätsmedizin Berlin, Berlin, Germany; Charité Comprehensive Cancer Center, Berlin, Germany
| | - U Keilholz
- Charité Comprehensive Cancer Center, Berlin, Germany
| |
Collapse
|
9
|
Leistenschneider E, Dunling E, Bollen G, Brown BA, Dilling J, Hamaker A, Holt JD, Jacobs A, Kwiatkowski AA, Miyagi T, Porter WS, Puentes D, Redshaw M, Reiter MP, Ringle R, Sandler R, Sumithrarachchi CS, Valverde AA, Yandow IT. Precision Mass Measurements of Neutron-Rich Scandium Isotopes Refine the Evolution of N=32 and N=34 Shell Closures. Phys Rev Lett 2021; 126:042501. [PMID: 33576685 DOI: 10.1103/physrevlett.126.042501] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 09/28/2020] [Accepted: 12/14/2020] [Indexed: 06/12/2023]
Abstract
We report high-precision mass measurements of ^{50-55}Sc isotopes performed at the LEBIT facility at NSCL and at the TITAN facility at TRIUMF. Our results provide a substantial reduction of their uncertainties and indicate significant deviations, up to 0.7 MeV, from the previously recommended mass values for ^{53-55}Sc. The results of this work provide an important update to the description of emerging closed-shell phenomena at neutron numbers N=32 and N=34 above proton-magic Z=20. In particular, they finally enable a complete and precise characterization of the trends in ground state binding energies along the N=32 isotone, confirming that the empirical neutron shell gap energies peak at the doubly magic ^{52}Ca. Moreover, our data, combined with other recent measurements, do not support the existence of a closed neutron shell in ^{55}Sc at N=34. The results were compared to predictions from both ab initio and phenomenological nuclear theories, which all had success describing N=32 neutron shell gap energies but were highly disparate in the description of the N=34 isotone.
Collapse
Affiliation(s)
- E Leistenschneider
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - E Dunling
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, University of York, York YO10 5DD, United Kingdom
| | - G Bollen
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - B A Brown
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Dilling
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - A Hamaker
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J D Holt
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, McGill University, 3600 Rue University, Montréal, Quebec H3A 2T8, Canada
| | - A Jacobs
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - A A Kwiatkowski
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia V8P 5C2, Canada
| | - T Miyagi
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - W S Porter
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - D Puentes
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Redshaw
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics, Central Michigan University, Mount Pleasant, Michigan 48859, USA
| | - M P Reiter
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- II. Physikalisches Institut, Justus-Liebig-Universität, 35392 Gießen, Germany
- School of Physics and Astronomy, University of Edinburgh, Edinburgh EH9 3FD, United Kingdom
| | - R Ringle
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - R Sandler
- Department of Physics, Central Michigan University, Mount Pleasant, Michigan 48859, USA
| | - C S Sumithrarachchi
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - A A Valverde
- Department of Physics & Astronomy, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - I T Yandow
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
10
|
Lemoine A, Van de Velde M, Jacobs A, Joshi G, Bonnet F. PROSPECT review methodology for oncological breast surgery: a reply. Anaesthesia 2020; 76:288-289. [PMID: 33080069 DOI: 10.1111/anae.15284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/22/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A Lemoine
- APHP - Sorbonne Université, Paris, France
| | | | - A Jacobs
- University Hospital, Leuven, Belgium
| | - G Joshi
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - F Bonnet
- APHP - Sorbonne Université, Paris, France
| |
Collapse
|
11
|
Lemoine A, Van de Velde M, Jacobs A, Joshi G, Bonnet F. PROSPECT guidelines for oncological breast surgery: the role of non-opioid analgesics, a reply. Anaesthesia 2020; 76:141-142. [PMID: 33015825 DOI: 10.1111/anae.15266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2020] [Indexed: 10/23/2022]
Affiliation(s)
- A Lemoine
- APHP - Sorbonne Université, Paris, France
| | | | - A Jacobs
- University Hospital, Leuven, Belgium
| | - G Joshi
- University of Texas Southwestern Medical Center, Dallas, USA
| | - F Bonnet
- APHP - Sorbonne Université, Paris, France
| |
Collapse
|
12
|
Lemoine A, Van de Velde M, Jacobs A, Joshi G, Bonnet F. Breast surgery analgesia: a reply. Anaesthesia 2020; 75:1406-1407. [PMID: 32654117 DOI: 10.1111/anae.15192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/12/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A Lemoine
- APHP - Sorbonne Université, Paris, France
| | | | - A Jacobs
- University Hospital, Leuven, Belgium
| | - G Joshi
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - F Bonnet
- APHP - Sorbonne Université, Paris, France
| |
Collapse
|
13
|
Jacobs A, Lemoine A, Joshi GP, Van de Velde M, Bonnet F. PROSPECT guideline for oncological breast surgery: a systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia 2020; 75:664-673. [PMID: 31984479 PMCID: PMC7187257 DOI: 10.1111/anae.14964] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2019] [Indexed: 12/17/2022]
Abstract
Analgesic protocols used to treat pain after breast surgery vary significantly. The aim of this systematic review was to evaluate the available literature on this topic and develop recommendations for optimal pain management after oncological breast surgery. A systematic review using preferred reporting items for systematic reviews and meta-analysis guidance with procedure-specific postoperative pain management (PROSPECT) methodology was undertaken. Randomised controlled trials assessing postoperative pain using analgesic, anaesthetic or surgical interventions were identified. Seven hundred and forty-nine studies were found, of which 53 randomised controlled trials and nine meta-analyses met the inclusion criteria and were included in this review. Quantitative analysis suggests that dexamethasone and gabapentin reduced postoperative pain. The use of paravertebral blocks also reduced postoperative pain scores, analgesia consumption and the incidence of postoperative nausea and vomiting. Intra-operative opioid requirements were documented to be lower when a pectoral nerves block was performed, which also reduced postoperative pain scores and opioid consumption. We recommend basic analgesics (i.e. paracetamol and non-steroidal anti-inflammatory drugs) administered pre-operatively or intra-operatively and continued postoperatively. In addition, pre-operative gabapentin and dexamethasone are also recommended. In major breast surgery, a regional anaesthetic technique such as paravertebral block or pectoral nerves block and/or local anaesthetic wound infiltration may be considered for additional pain relief. Paravertebral block may be continued postoperatively using catheter techniques. Opioids should be reserved as rescue analgesics in the postoperative period. Research is needed to evaluate the role of novel regional analgesic techniques such as erector spinae plane or retrolaminar plane blocks combined with basic analgesics in an enhanced recovery setting.
Collapse
Affiliation(s)
- A. Jacobs
- Department of Cardiovascular SciencesKULeuven and University Hospital LeuvenLeuvenBelgium
| | - A. Lemoine
- Service d'Anesthésie – Réanimation et Médecine Péri‐opératoireHopital TenonAPHPParis, France/Médecine‐Sorbonne UniversitéParisFrance
| | - G. P. Joshi
- Department of Anesthesiology and Pain ManagementUniversity of Texas Southwestern Medical CenterDallasTXUSA
| | - M. Van de Velde
- Department of Cardiovascular SciencesKULeuven and University Hospital LeuvenLeuvenBelgium
| | - F. Bonnet
- Service d'Anesthésie – Réanimation et Médecine Péri‐opératoireHopital TenonAPHPParis, France/Médecine‐Sorbonne UniversitéParisFrance
| |
Collapse
|
14
|
Jacobs A, Njus M, Rahman S, Malone P, Thakkar R, Lynskey E. Abstract No. 644 Characterizing renal and hepatic function markers in patients who receive transjugular portosystemic shunt for refractory ascites. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
15
|
van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, de Groot M, de Jong EMGJ, Kemperman PMJH, de Kort WJA, Karsch SA, Lamberts A, Lecluse LLA, van Lümig PPM, Menting SP, Prens EP, van den Reek JMPA, Seyger MMB, Thio HB, Veldkamp WR, Wakkee M, Nast A, Jacobs A, Rosumeck S, Spuls Chair PI. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180:31-42. [PMID: 30604536 PMCID: PMC6849803 DOI: 10.1111/bjd.17198] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2018] [Indexed: 12/31/2022]
Abstract
Linked Comment: https://doi.org/10.1111/bjd.17390.
Collapse
Affiliation(s)
- G E van der Kraaij
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.,Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.,Dutch Society of Dermatology and Venereology, Utrecht, the Netherlands
| | - D M W Balak
- University Medical Centre Utrecht, Utrecht, the Netherlands
| | - C I Busard
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.,Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - O D van Cranenburgh
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.,Dutch Skin Foundation, Nieuwegein, the Netherlands
| | - Y Chung
- Dutch Society of Dermatology and Venereology, Utrecht, the Netherlands
| | - R J B Driessen
- Radboud University Medical Centre, Nijmegen, the Netherlands
| | - M de Groot
- Antonius Hospital, Sneek/Emmeloord, the Netherlands
| | - E M G J de Jong
- Radboud University Medical Centre, Nijmegen, the Netherlands.,Radboud University Nijmegen, the Netherlands
| | - P M J H Kemperman
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.,Waterlandziekenhuis, Purmerend, the Netherlands
| | | | - S A Karsch
- Dutch Society of Dermatology and Venereology, Utrecht, the Netherlands
| | - A Lamberts
- Dutch Society of Dermatology and Venereology, Utrecht, the Netherlands.,University Medical Center Groningen, Groningen, the Netherlands
| | - L L A Lecluse
- Bergman Clinics and U-clinic, Amsterdam, the Netherlands
| | - P P M van Lümig
- Radboud University Medical Centre, Nijmegen, the Netherlands
| | - S P Menting
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - E P Prens
- Erasmus Medical Centre, Rotterdam, the Netherlands
| | | | - M M B Seyger
- Radboud University Medical Centre, Nijmegen, the Netherlands
| | - H B Thio
- Erasmus Medical Centre, Rotterdam, the Netherlands
| | - W R Veldkamp
- Dutch Society of Dermatology and Venereology, Utrecht, the Netherlands.,Radboud University Nijmegen, the Netherlands
| | - M Wakkee
- Erasmus Medical Centre, Rotterdam, the Netherlands
| | - A Nast
- Department of Dermatology, Venereology und Allergy, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - A Jacobs
- Department of Dermatology, Venereology und Allergy, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - S Rosumeck
- Department of Dermatology, Venereology und Allergy, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - P I Spuls Chair
- Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.,Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|
16
|
Cusick JK, Alhomsy Y, Talbott G, Sumida C, Aghaians D, Hejazi N, Jacobs A. RELT stains prominently in B cell lymphomas and binds proteins associated with leukemia. The Journal of Immunology 2019. [DOI: 10.4049/jimmunol.202.supp.194.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Receptor Expressed in Lymphoid Tissues (RELT) is a human TNFR that is expressed prominently in the hematopoietic system and negatively regulates T-cell activation in mice. RELT has two identified homologous binding partners, RELL1 and RELL2. This study sought to further elucidate the function of RELT by identifying novel protein interactions with RELT family members and to study the localization of RELT in both normal and diseased tissues. A yeast two-hybrid screen identifed Phospholipid Scramblase 1 (PLSCR1) and MyoD family inhibitor domain-containing protein (MDFIC) as potential RELT-family member binding proteins that were confirmed by in vitro co-immunoprecipitations. PLSCR1 has been demonstrated to possess anti-leukemic properties, and RELT expression results in an altered cellular localization of PLSCR1 as determined by immunofluorescence (IF). The MDFIC gene encodes for a transcription factor and is located proximally to regions of chromosome 7 (7q31.1) frequently lost in AML patients. MDFIC was observed to co-localize with RELL1 at the plasma membrane and co-localize with RELT in intracellular compartments as determined by IF. Since RELT, PLSCR1 and MDFIC are prominently expressed in the hematopoietic system, we sought to characterize the expression of RELT in both normal lymph nodes and B cell lymphomas. Immunohistochemistry revealed a higher intensity of RELT staining in germinal centers in comparison to surrounding lymph node regions. Interestingly, the level of RELT staining increased progressively in low and high-grade B cell lymphomas versus normal lymph nodes. Collectively, these results further our understanding of proteins that interact with RELT and identify an association of RELT with B cell lymphomas.
Collapse
|
17
|
Verstraelen S, Van Rompay A, Jacobs A, Hollanders K, Boonen F, Geukens G, Frijns E, Geerts L, Weltens R. Hazard assessment for a Ti-based nano-additived material: from core-shell production to final part. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 2018; 194:295-314. [PMID: 30144037 PMCID: PMC6231011 DOI: 10.1111/cei.13208] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/27/2018] [Indexed: 01/05/2023] Open
Abstract
Alemtuzumab, a humanized anti‐CD52 monoclonal antibody, is approved for treatment of relapsing multiple sclerosis (MS). In the Phase II/III trials, patients received 12 or 24 mg/day of alemtuzumab in two treatment courses (5 days for course 1 and 3 days for course 2), 12 months apart. Serum concentrations of alemtuzumab peaked on the last day of dosing in each course and mostly fell below the limit of quantitation by day 30. Alemtuzumab rapidly depleted circulating T and B lymphocytes, with the lowest observed values occurring within days. Lymphocytes repopulated over time, with B cell recovery usually complete within 6 months. T lymphocytes recovered more slowly and generally did not return to baseline by 12 months post‐treatment. Approximately 40 and 80% of patients had total lymphocyte counts, reaching the lower limit of normal by 6 and 12 months after each course, respectively. The clearance of alemtuzumab is dependent on circulating lymphocyte count. A majority of treated patients tested positive for anti‐alemtuzumab antibodies, including inhibitory antibodies, during the 2‐year studies, and a higher proportion of patients tested positive in course 2 than in course 1. The presence of anti‐alemtuzumab antibody appeared to be associated with slower clearance of alemtuzumab from the circulation but had no impact on the pharmacodynamics. No effects of age, race or gender on the pharmacokinetics or pharmacodynamics were observed. Together, the pharmacokinetics, pharmacodynamics and immunogenicity results support the continued development and use of alemtuzumab for the treatment of MS, and probably explain its sustained effects beyond the dosing interval.
Collapse
Affiliation(s)
- Z Li
- Sanofi, Cambridge, MA, USA
| | | | | | | | | |
Collapse
|
19
|
Jacobs A, De Noia M, Praebel K, Kanstad-Hanssen Ø, Paterno M, Jackson D, McGinnity P, Sturm A, Elmer KR, Llewellyn MS. Genetic fingerprinting of salmon louse (Lepeophtheirus salmonis) populations in the North-East Atlantic using a random forest classification approach. Sci Rep 2018; 8:1203. [PMID: 29352185 PMCID: PMC5775277 DOI: 10.1038/s41598-018-19323-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Accepted: 12/17/2017] [Indexed: 12/13/2022] Open
Abstract
Caligid sea lice represent a significant threat to salmonid aquaculture worldwide. Population genetic analyses have consistently shown minimal population genetic structure in North Atlantic Lepeophtheirus salmonis, frustrating efforts to track louse populations and improve targeted control measures. The aim of this study was to test the power of reduced representation library sequencing (IIb-RAD sequencing) coupled with random forest machine learning algorithms to define markers for fine-scale discrimination of louse populations. We identified 1286 robustly supported SNPs among four L. salmonis populations from Ireland, Scotland and Northern Norway. Only weak global structure was observed based on the full SNP dataset. The application of a random forest machine-learning algorithm identified 98 discriminatory SNPs that dramatically improved population assignment, increased global genetic structure and resulted in significant genetic population differentiation. A large proportion of SNPs found to be under directional selection were also identified to be highly discriminatory. Our data suggest that it is possible to discriminate between nearby L. salmonis populations given suitable marker selection approaches, and that such differences might have an adaptive basis. We discuss these data in light of sea lice adaption to anthropogenic and environmental pressures as well as novel approaches to track and predict sea louse dispersal.
Collapse
Affiliation(s)
- A Jacobs
- Institute of Biodiversity, Animal Health & Comparative Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK
| | - M De Noia
- Institute of Biodiversity, Animal Health & Comparative Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK
| | - K Praebel
- Norwegian College of Fishery Science, UiT The Arctic University of Norway, N-9037, Tromsø, Norway
| | | | - M Paterno
- Department of Biology, University of Padova, Padova, Italy
| | | | - P McGinnity
- School of Biological, Earth and Environmental Sciences, University College Cork, Cork, Ireland
| | - A Sturm
- Institute of Aquaculture, University of Stirling, Stirling, UK
| | - K R Elmer
- Institute of Biodiversity, Animal Health & Comparative Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK
| | - M S Llewellyn
- Institute of Biodiversity, Animal Health & Comparative Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
| |
Collapse
|
20
|
Conrad M, Crosby W, Jacobs A, Kaltwasser J, Nusbacher J. The Hippocratian Principle of ‘primum nil nocere’ Demands
that the Metabolic State of a Donor Should Be Normalized
Prior to a Subsequent Donation of Blood or Plasma. How
Much Blood, Relative to His Body Weight, Can a Donor
Give over a Certain Period, Without a Continuous Deviation
of Iron Metabolism in the Direction of Iron Deficiency? Vox Sang 2017. [DOI: 10.1159/000460670] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
21
|
Cusick JK, Moua P, Talbott G, Sumida C, Jacobs A. RELT binds HIC and induces apoptosis by a mechanism distinct from TNFR1. The Journal of Immunology 2017. [DOI: 10.4049/jimmunol.198.supp.201.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Receptor Expressed in Lymphoid Tissues (RELT) is a human Tumor Necrosis Factor Receptor (TNFR) that is expressed most prominently in cells and tissues of the hematopoietic system. RELT has two identified homologous binding partners RELL1 and RELL2. This study sought to further elucidate the function of RELT by identifying novel protein interactions with RELT family members. Human I-mfa domain-containing protein (HIC), also known as MDFIC, was identified in a yeast two-hybrid genetic screen using RELL1 as bait. HIC is a transcription factor that was initially identified to differentially regulate HTLV and HIV gene expression. HIC is now known to regulate many other cellular processes and the hic gene is located proximally to regions of chromosome 7 (7q31.1) frequently lost in Acute Myeloid Leukemia (AML) patients. HIC physically interacts with both RELT and RELL1, as determined by in vitro co-immunoprecipitations. HIC co-localizes with RELL1 at the plasma membrane and co-localizes with RELT in intracellular compartments. Deletion mutants of RELT were utilized to determine regions of RELT required for both the activation of p38 and the induction of apoptosis in HEK-293 cells, two previously described functions of RELT. Co-immunoprecipitation experiments utilizing the deletion mutants indicate that regions of RELT proximal to the plasma membrane are sufficient for physical interaction with HIC. Overexpression of RELT induces cleavage of PARP and Caspase-3 as determined by western blotting. Interestingly, induction of apoptotic morphology by RELT overexpression was not prevented if signaling by FADD or Caspase-8 was blocked, indicating RELT induces apoptosis by a pathway distinct from death-domain containing TNFRs such as TNFR1.
Collapse
Affiliation(s)
- John K Cusick
- 1California University of Science and Medicine
- 2California Northstate University, College of Pharmacy
| | - Pachai Moua
- 2California Northstate University, College of Pharmacy
| | | | - Cara Sumida
- 3University of Hawaii at Hilo, College of Pharmacy
| | - Aaron Jacobs
- 3University of Hawaii at Hilo, College of Pharmacy
| |
Collapse
|
22
|
Connelly L, Yadav N, Barcikowski A, Imaizumi Y, Jacobs A. Abstract P4-03-13: Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-03-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Obese individuals with breast cancer have a poorer prognosis and higher risk of metastatic disease vs. non-obese patients. Prior research has largely focused on defining the interactions between adipocytes and tumor cells, but other cell types may also play a role. Adipose tissue in obese individuals is characterized by a significant infiltration of macrophages. We have therefore investigated the adipocyte-macrophage interaction as a possible mechanism whereby obesity promotes breast cancer metastasis.
We performed co-culture with both human and murine cells to determine whether adipocytes influence the expression of metastasis-promoting signals in macrophages. For the human system we co-cultured primary breast adipocytes with THP-1 macrophages. For the murine system we co-cultured 3T3-L1 differentiated adipocytes with J774.1 macrophages. We then assayed the mRNA levels and protein expression of metastasis-promoting genes.
In both systems we found that co-culture with adipocytes increased the expression of Vascular Endothelial Growth Factor A (VEGF-A) in macrophages. In examining a potential mechanism, we also show that media collected from cultured adipocytes (adipocyte-conditioned media) activates the transcription factor Egr-1 in macrophages. Since Egr-1 is a known regulator of VEGF-A expression, this is a potential mechanism whereby VEGF-A transcription is up-regulated. Treatment of human macrophages with Interleukin-6, Leptin and Insulin induced VEGF-A levels to a similar degree as co-culture, identifying these as adipocyte-derived signals that can possibly mediate this effect.
In summary we have found that the interaction between adipocytes and macrophages leads to the up-regulation of the pro-angiogenic signal VEGF-A in macrophages. Therefore this represents a potential mechanism whereby obesity could promote breast cancer metastasis.
Citation Format: Connelly L, Yadav N, Barcikowski A, Imaizumi Y, Jacobs A. Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-13.
Collapse
Affiliation(s)
| | - N Yadav
- University of Hawaii at Hilo, Hilo, HI
| | | | | | - A Jacobs
- University of Hawaii at Hilo, Hilo, HI
| |
Collapse
|
23
|
Schlager J, Rosumeck S, Werner R, Jacobs A, Schmitt J, Schlager C, Nast A. Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol 2016; 176:604-614. [DOI: 10.1111/bjd.14811] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/20/2016] [Indexed: 02/05/2023]
Affiliation(s)
- J.G. Schlager
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - S. Rosumeck
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - R.N. Werner
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - A. Jacobs
- Department of Medical Consulting; Federal Joint Committee (G-BA, Gemeinsamer Bundesausschuss); Wegelystr. 8 10623 Berlin Germany
| | - J. Schmitt
- Zentrum für evidenzbasierte Gesundheitsversorgung (ZEGV); Medical Faculty Carl Gustav Carus; Technischen Universität Dresden; Fetscherstraße 74 01307 Dresden Germany
| | - C. Schlager
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - A. Nast
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| |
Collapse
|
24
|
Roozen NB, Glorieux C, Liu L, Rychtáriková M, Van der Donck T, Jacobs A. Converting sunlight into audible sound by means of the photoacoustic effect: The Heliophone. J Acoust Soc Am 2016; 140:1697. [PMID: 27914443 DOI: 10.1121/1.4962493] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
One hundred and thirty-five years after Alexander Graham Bell and his assistant Charles Sumner Tainter explored the photoacoustic effect, and about 40 years after Rosencwaig and Gersho modeled the effect in a photoacoustic cell configuration, the phenomenon is revisited in a "Heliophone" device that converts sunlight into sound. The light is focused on a carbon blackened copper coated Kapton foil in an acoustic cell by means of a compound parabolic collimator, and its intensity is modulated by a mechanical chopper. A horn is employed to make the sound audible without electronic amplification. The description of the photoacoustic effect that was introduced by Rosencwaig and Gersho is extended to a cell-horn configuration, in which the periodically heated air above the foil acts as an oscillating piston, driving acoustic waves in the horn. The pressure in the cavity-horn assembly is calculated by considering the air layer piston as an equivalent volume velocity source. The importance of the carbon black (soot) layer to enhance light absorption, but above all to enhance the photothermal excitation efficiency, is elucidated by means of an experimentally supported physical model.
Collapse
Affiliation(s)
- N B Roozen
- Laboratory of Acoustics, Division Soft Matter and Biophysics, Department of Physics and Astronomy, KU Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - C Glorieux
- Laboratory of Acoustics, Division Soft Matter and Biophysics, Department of Physics and Astronomy, KU Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - L Liu
- Laboratory of Acoustics, Division Soft Matter and Biophysics, Department of Physics and Astronomy, KU Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - M Rychtáriková
- STU Bratislava, Faculty of Civil Engineering, Department of Building Structures, Radlinskeho 11, Bratislava, 810 05, Slovak Republic
| | - T Van der Donck
- Department of Materials Engineering, KU Leuven, Kasteelpark Arenberg 44, 3001 Leuven, Belgium
| | - A Jacobs
- Overtoon, Platform for Sound Art, Luchtvaartsquare 19, 1070, Brussels, Belgium
| |
Collapse
|
25
|
Leblanc V, Adriaens E, Grandidier M, Hollanders K, Jacobs A, Meloni M, Nardelli L, Roper C, Van Rompay A, Vinall J, Cotovio J, Alepée N. SkinEthic™ HCE eye irritation test method on solid and liquid chemicals: Reliability, relevance and contribution to serious eye damage/eye irritation global assessment. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
26
|
Mewes KR, Fischer A, Zöller NN, Laubach V, Bernd A, Jacobs A, van Rompay A, Liebsch M, Pirow R, Petersohn D. Catch-up validation study of an in vitro skin irritation test method based on an open source reconstructed epidermis (phase I). Toxicol In Vitro 2016; 36:238-253. [PMID: 27432483 DOI: 10.1016/j.tiv.2016.07.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 06/30/2016] [Accepted: 07/13/2016] [Indexed: 11/19/2022]
Abstract
We have developed a new in vitro skin irritation test based on an open source reconstructed epidermis (OS-REp) with openly accessible protocols for tissue production and test performance. Due to structural, mechanistic and procedural similarity, a blinded catch-up validation study for skin irritation according to OECD Performance Standards (PS) was conducted in three laboratories to promote regulatory acceptance, with OS-REp models produced at a single production site only. While overall sensitivity and predictive capacity met the PS requirements, overall specificity was only 57%. A thorough analysis of the test results led to the assumption that some of the false-positive classifications could have been evoked by volatile skin-irritating chemicals tested in the same culture plate as the non-irritants falsely predicted as irritants. With GC/MS and biological approaches the cross-contamination effect was confirmed and the experimental set-up adapted accordingly. Retesting of the affected chemicals with the improved experimental set-up and otherwise identical protocol resulted in correct classifications as non-irritants. Taking these re-test results into account, 93% overall sensitivity, 70% specificity and 82% accuracy was achieved, which is in accordance with the OECD PS. A sufficient reliability of the method was indicated by a within-laboratory-reproducibility of 85-95% and a between-laboratory-reproducibility of 90%.
Collapse
Affiliation(s)
- K R Mewes
- Henkel AG & Co. KGaA, Henkelstr. 67, 40589 Düsseldorf, Germany.
| | - A Fischer
- Henkel AG & Co. KGaA, Henkelstr. 67, 40589 Düsseldorf, Germany
| | - N N Zöller
- Goethe-University, Medical School, Department of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - V Laubach
- Goethe-University, Medical School, Department of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - A Bernd
- Goethe-University, Medical School, Department of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - A Jacobs
- VITO NV Flemish Institute for Technological Research, Environmental Risk and Health Unit, Boeretang 200, 2400 Mol, Belgium
| | - A van Rompay
- VITO NV Flemish Institute for Technological Research, Environmental Risk and Health Unit, Boeretang 200, 2400 Mol, Belgium
| | - M Liebsch
- Bundesinstitut für Risikobewertung (BfR), Max-Dohrn-Straße 8-10, 10589 Berlin, Germany
| | - R Pirow
- Bundesinstitut für Risikobewertung (BfR), Max-Dohrn-Straße 8-10, 10589 Berlin, Germany
| | - D Petersohn
- Henkel AG & Co. KGaA, Henkelstr. 67, 40589 Düsseldorf, Germany
| |
Collapse
|
27
|
Jacobs A, Brown P, Wilkin J. Letter to the Editor. Int J Toxicol 2016. [DOI: 10.1080/109158100225060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- A. Jacobs
- Division of Dermatologic and Dental Drug Products CDER, FDA
| | - P. Brown
- Division of Dermatologic and Dental Drug Products CDER, FDA
| | - J. Wilkin
- Division of Dermatologic and Dental Drug Products CDER, FDA
| |
Collapse
|
28
|
Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Agostino SD, Blandino G, Avantaggiati ML, Chung FL. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ 2016; 23:1615-27. [PMID: 27258787 PMCID: PMC5041190 DOI: 10.1038/cdd.2016.48] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 04/11/2016] [Accepted: 04/26/2016] [Indexed: 12/20/2022] Open
Abstract
Mutations in the p53 tumor-suppressor gene are prevalent in human cancers. The majority of p53 mutations are missense, which can be classified into contact mutations (that directly disrupts the DNA-binding activity of p53) and structural mutations (that disrupts the conformation of p53). Both of the mutations can disable the normal wild-type (WT) p53 activities. Nevertheless, it has been amply documented that small molecules can rescue activity from mutant p53 by restoring WT tumor-suppressive functions. These compounds hold promise for cancer therapy and have now entered clinical trials. In this study, we show that cruciferous-vegetable-derived phenethyl isothiocyanate (PEITC) can reactivate p53 mutant under in vitro and in vivo conditions, revealing a new mechanism of action for a dietary-related compound. PEITC exhibits growth-inhibitory activity in cells expressing p53 mutants with preferential activity toward p53R175, one of the most frequent ‘hotspot' mutations within the p53 sequence. Mechanistic studies revealed that PEITC induces apoptosis in a p53R175 mutant-dependent manner by restoring p53 WT conformation and transactivation functions. Accordingly, in PEITC-treated cells the reactivated p53R175 mutant induces apoptosis by activating canonical WT p53 targets, inducing a delay in S and G2/M phase, and by phosphorylating ATM/CHK2. Interestingly, the growth-inhibitory effects of PEITC depend on the redox state of the cell. Further, PEITC treatments render the p53R175 mutant sensitive to degradation by the proteasome and autophagy in a concentration-dependent manner. PEITC-induced reactivation of p53R175 and its subsequent sensitivity to the degradation pathways likely contribute to its anticancer activities. We further show that dietary supplementation of PEITC is able to reactivate WT activity in vivo as well, inhibiting tumor growth in xenograft mouse model. These findings provide the first example of mutant p53 reactivation by a dietary compound and have important implications for cancer prevention and therapy.
Collapse
Affiliation(s)
- M Aggarwal
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - R Saxena
- Department of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, DC 20007, USA
| | - E Sinclair
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - Y Fu
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - A Jacobs
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - M Dyba
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - X Wang
- National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | - I Cruz
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - D Berry
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - B Kallakury
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - S C Mueller
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - S D Agostino
- Translational Oncogenomics Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy
| | - G Blandino
- Translational Oncogenomics Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy
| | - M L Avantaggiati
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| | - F-L Chung
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
| |
Collapse
|
29
|
Eikelenboom N, van Lieshout J, Jacobs A, Verhulst F, Lacroix J, van Halteren A, Klomp M, Smeele I, Wensing M. [Supporting patients in self-management: moving to a personalised approach]. Ned Tijdschr Geneeskd 2016; 160:D758. [PMID: 27879183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVE The aim of this research was to assess the effect of providing personalised self-management support on patient activation (knowledge, skills, self-efficacy) and self-management behaviour. DESIGN Cluster randomised trial in 15 general practices (Dutch Trial Register No.: NTR 3960). METHOD Patients aged 18 years or older with a chronic condition were invited to participate in the study. The Self-Management Screening (SeMaS) questionnaire - which illustrates barriers to self-management - was used as a tool for personalised self-management support. Nurse practitioners in the intervention practices were trained for 2 hours in using SeMaS and personalising self-management support on the basis of the SeMaS profile. At baseline and after 6 months, patients filled in questionnaires on patient activation (PAM-13) and lifestyle. Using data from the questionnaires and medical records, the use of individual care plans, referrals to self-management interventions, self-monitoring and healthcare use were assessed. We used a multiple multilevel regression model for data analysis. RESULTS After 6 months, no difference was found in patient activation between the control group (n = 348) and the intervention group (n = 296). 29.4% of the patients in the intervention group performed self-monitoring, versus 15.2% in the control group (regression coefficient r = 0.9, p = 0.01). In the per-protocol analysis (control n = 348; intervention n = 136), the number of individual care plans (r = 1.3, p = 0.04) and the number of patients performing self-monitoring (r = 1.0; p = 0.01) were higher in the intervention group. CONCLUSION Personalised self-management support with the use of the SeMaS method stimulates self-monitoring and the use of individual care plans. The intervention had no effect on patient activation or lifestyle. Given the positive secondary outcomes, the further potential of the tool should be researched.
Collapse
Affiliation(s)
- N Eikelenboom
- * Dit onderzoek werd eerder gepubliceerd in The British Journal of General Practice (2016;66:e354-61) met als titel 'Effectiveness of personalised support for self-management in primary care: a cluster randomised controlled trial'. Afgedrukt met toestemming
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Jacobs A, Harks F, Hoeijmakers M, Segers R. Erratum to: A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars. Porcine Health Manag 2015; 1:20. [PMID: 28409569 PMCID: PMC5382379 DOI: 10.1186/s40813-015-0014-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A Jacobs
- MSD Animal Health, Wim de Körverstraat 35, Boxmeer, 5830 AA The Netherlands
| | - F Harks
- MSD Animal Health, Wim de Körverstraat 35, Boxmeer, 5830 AA The Netherlands
| | - M Hoeijmakers
- MSD Animal Health, Wim de Körverstraat 35, Boxmeer, 5830 AA The Netherlands
| | - R Segers
- MSD Animal Health, Wim de Körverstraat 35, Boxmeer, 5830 AA The Netherlands
| |
Collapse
|
31
|
Jacobs A, Harks F, Hoeijmakers M, Segers R. A novel octavalent combined Erysipelas, Parvo and Leptospira vaccine provides (cross) protection against infection following challenge of pigs with 9 different Leptospira interrogans serovars. Porcine Health Manag 2015; 1:16. [PMID: 28405422 PMCID: PMC5382398 DOI: 10.1186/s40813-015-0011-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 11/06/2015] [Indexed: 11/28/2022] Open
Abstract
Background In the present study the efficacy and cross protection of a novel ready-to-use combination vaccine, Porcilis® Ery + Parvo + Lepto, against swine leptospirosis, was investigated. The octavalent vaccine contains inactivated antigens of Erysipelothrix rhusiopathiae, Parvovirus and 6 Leptospira interrogans sensu lato strains of serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis (Bratislava), Pomona and Tarassovi. In this study ninety pigs were vaccinated twice with Porcilis® Ery + Parvo + Lepto at six and ten weeks of age and ninety age and source-matched animals served as unvaccinated control. Two weeks after booster vaccination, groups of vaccinated and control pigs (ten pigs per group) were challenged with fresh virulent cultures of either of the nine different challenge strains. Compared to the vaccine strains the challenge strains were heterologous strains of the same serovar or of a different serovar within the same serogroup. The challenge strains tested were of serovar Canicola, Icterohaemorrhagiae, Copenhageni (serogroup Icterohaemorrhagiae), Grippotyphosa, Bananal/Liangguan (serogroup Grippotyphosa), Pomona, Tarassovi and Vughia (serogroup Tarassovi). Results After the different challenges most control animals became leptospiraemic for 2–7 days. The vaccinated pigs remained blood culture negative except for two animals after serovar Icterohaemorrhagiae and two animals after serovar Tarassovi challenge which became leptospiraemic for only 1 day. The incidence of Leptospiraemia (as determined by blood culture) was significantly less in vaccinates compared to the controls after all challenges. The vaccine also prevented renal infection and urinary shedding after serovar Canicola challenge. The other serovars did not induce detectable renal infection or urinary shedding. Conclusion The present study demonstrates that the new combination vaccine Porcilis® Ery + Parvo + Lepto induces significant (cross) protection against nine different serovars within the serogroups Canicola, Icterohaemorrhagiae, Grippotyphosa, Australis (Bratislava), Pomona and Tarassovi.
Collapse
Affiliation(s)
- A Jacobs
- MSD Animal Health, Wim de Körverstraat 35, PO Box 31, 5830 AA Boxmeer, The Netherlands
| | - F Harks
- MSD Animal Health, Wim de Körverstraat 35, PO Box 31, 5830 AA Boxmeer, The Netherlands
| | - M Hoeijmakers
- MSD Animal Health, Wim de Körverstraat 35, PO Box 31, 5830 AA Boxmeer, The Netherlands
| | - R Segers
- MSD Animal Health, Wim de Körverstraat 35, PO Box 31, 5830 AA Boxmeer, The Netherlands
| |
Collapse
|
32
|
Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29:2277-94. [PMID: 26481193 DOI: 10.1111/jdv.13354] [Citation(s) in RCA: 302] [Impact Index Per Article: 33.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 07/07/2015] [Indexed: 12/19/2022]
Affiliation(s)
- A Nast
- Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - P Gisondi
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A D Ormerod
- Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK
| | - P Saiag
- Service de Dermatologie, Hôpital Ambroise Paré Université Paris V, Boulogne, France
| | - C Smith
- Clinical Lead for Dermatology, St Johns Institute of Dermatology, St Thomas' Hospital, London, UK
| | - P I Spuls
- Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands
| | - P Arenberger
- Third Faculty of Medicine, Department of Dermatology, Charles University, Prague, Czech Republic
| | - H Bachelez
- Department of Dermatology, Hôpital Saint-Louis, Paris, France
| | - J Barker
- St. Johns Institute of Dermatology, St. Thomas' Hospital, London, UK
| | - E Dauden
- Hospital Universitario de la Princesa, Madrid, Spain
| | - E M de Jong
- University Medical Center Nijmegen St Radboud, Nijmegen, The Netherlands
| | - E Feist
- Medizinische Klinik mit Schwerpunkt Rheumatologie u. klinische Immonologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Jacobs
- Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | | | - L Kemény
- SZTE Borgyogyaszati Klinika, Szeged, Hungary
| | | | - U Mrowietz
- Department of Dermatology, Psoriasis-Center University Medical Center Schleswig Holstein, Kiel, Germany
| | | | - C Paul
- Department of Dermatology, Paul Sabatier University, Toulouse, France
| | - K Reich
- Dermatologikum Hamburg, Hamburg, Germany
| | - S Rosumeck
- Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - T Talme
- Section of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
| | - H B Thio
- Department of Dermatology, Erasmus University, Rotterdam, The Netherlands
| | - P van de Kerkhof
- Department of Dermatology, University Hospital Nijmegen, Nijmegen, The Netherlands
| | - R N Werner
- Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - N Yawalkar
- Department of Dermatology, Inselspital, Universitätsklinik für Dermatologie, Bern, Switzerland
| |
Collapse
|
33
|
Nast A, Jacobs A, Rosumeck S, Werner RN. Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29:e1-22. [PMID: 26471228 DOI: 10.1111/jdv.13353] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 07/24/2015] [Indexed: 11/28/2022]
Affiliation(s)
- A Nast
- Division of Evidence Based Medicine, Klinik für Dermatologie, Allergologie und Venerologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Jacobs
- Division of Evidence Based Medicine, Klinik für Dermatologie, Allergologie und Venerologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Rosumeck
- Division of Evidence Based Medicine, Klinik für Dermatologie, Allergologie und Venerologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - R N Werner
- Division of Evidence Based Medicine, Klinik für Dermatologie, Allergologie und Venerologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
34
|
Jacobs A, Rosumeck S, Nast A. Systematic review on the maintenance of response during systemic antipsoriatic therapy. Br J Dermatol 2015; 173:910-21. [DOI: 10.1111/bjd.14077] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/21/2015] [Indexed: 12/30/2022]
Affiliation(s)
- A. Jacobs
- Division of Evidence Based Medicine; Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - S. Rosumeck
- Division of Evidence Based Medicine; Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - A. Nast
- Division of Evidence Based Medicine; Department of Dermatology; Charité - Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| |
Collapse
|
35
|
Leblanc V, Adriaens E, Grandidier MH, Hollanders K, Jacobs A, Meloni M, Nardelli L, Roper C, Santirocco E, Toner F, Van Rompay A, Vinall J, Cotovio J, Alepee N. Serious eye damage/eye irritation assessment: How SkinEthic™ HCE reconstructed human corneal test method can address this area for liquid test substances. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Werner R, Stockfleth E, Connolly S, Correia O, Erdmann R, Foley P, Gupta A, Jacobs A, Kerl H, Lim H, Martin G, Paquet M, Pariser D, Rosumeck S, Röwert-Huber HJ, Sahota A, Sangueza O, Shumack S, Sporbeck B, Swanson N, Torezan L, Nast A. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol 2015; 29:2069-79. [DOI: 10.1111/jdv.13180] [Citation(s) in RCA: 188] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Accepted: 04/02/2015] [Indexed: 12/22/2022]
Affiliation(s)
- R.N. Werner
- Division of Evidence Based Medicine (dEBM), Department of Dematology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - E. Stockfleth
- Department of Dermatology, Venerology and Allergology; Skin Cancer Center (HTCC); Charité - Universitätsmedizin Berlin; Berlin Germany
| | - S.M. Connolly
- Department of Dermatology; Mayo Clinic; Scottsdale Arizona USA
| | - O. Correia
- Centro Dermatologia Epidermis; Instituto CUF and Faculty of Medicine of University of Porto; Porto Portugal
| | - R. Erdmann
- Division of Evidence Based Medicine (dEBM), Department of Dematology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - P. Foley
- Skin and Cancer Foundation Victoria; Carlton Victoria Australia
- St. Vincent's Hospital Melbourne; Fitzroy Victoria Australia
- The University of Melbourne; Melbourne Victoria Australia
| | - A.K. Gupta
- Division of Dermatology; Department of Medicine; University of Toronto; Toronto Ontario Canada
- Mediprobe Research Inc.; London Ontario Canada
| | - A. Jacobs
- Division of Evidence Based Medicine (dEBM), Department of Dematology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - H. Kerl
- Department of Dermatology; Medical University of Graz; Graz Austria
| | - H.W. Lim
- Department of Dermatology; Henry Ford Hospital; Detroit Michigan USA
| | - G. Martin
- Dermatology Laser Center of Maui; Kihei Hawaii USA
| | - M. Paquet
- Mediprobe Research Inc.; London Ontario Canada
| | - D.M. Pariser
- Division of Dermatology and Virginia Clinical Research Inc; Eastern Virginia Medical School; Norfolk Virginia USA
| | - S. Rosumeck
- Division of Evidence Based Medicine (dEBM), Department of Dematology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - H.-J. Röwert-Huber
- Division of Dermatopathology; Department of Dermatology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - A. Sahota
- Department of Dermatology; Whipps Cross University Hospital; London UK
| | - O.P. Sangueza
- Department of Pathology; Wake Forest Baptist Medical Center; Winston-Salem North Carolina USA
- Department of Dermatology; Wake Forest Baptist Medical Center; Winston-Salem North Carolina USA
| | - S. Shumack
- Department of Dermatology; Northern Medical School; University of Sydney; Sydney New South Wales Australia
| | - B. Sporbeck
- Division of Evidence Based Medicine (dEBM), Department of Dematology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| | - N.A. Swanson
- Dermatology, Surgery, and Otolaryngology; Oregon Health and Science University; Portland Oregon USA
- Surgical and Cosmetic Dermatology and Clinical Operations; Oregon Health and Science University Knight Cancer Institute; Portland Oregon USA
| | - L. Torezan
- Faculty of Medicine; Hospital das Clínicas; Universidade de São Paulo; São Paulo Brazil
| | - A. Nast
- Division of Evidence Based Medicine (dEBM), Department of Dematology, Venerology and Allergology; Charité - Universitätsmedizin Berlin; Berlin Germany
| |
Collapse
|
37
|
Werner RN, Jacobs A, Rosumeck S, Erdmann R, Sporbeck B, Nast A. Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum. J Eur Acad Dermatol Venereol 2015; 29:e1-66. [PMID: 26350885 DOI: 10.1111/jdv.13179] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Accepted: 04/03/2015] [Indexed: 12/01/2022]
Affiliation(s)
- R N Werner
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Jacobs
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Rosumeck
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - R Erdmann
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - B Sporbeck
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Nast
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
38
|
Werner RN, Jacobs A, Rosumeck S, Erdmann R, Sporbeck B, Nast A. Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum. J Eur Acad Dermatol Venereol 2015. [PMID: 26350885 DOI: 10.111/jvd.13179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- R N Werner
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Jacobs
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Rosumeck
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - R Erdmann
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - B Sporbeck
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - A Nast
- Division of Evidence Based Medicine (dEBM), Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
39
|
Affiliation(s)
- A Jacobs
- Department of Haematology, University of Wales College of Medicine, Cardiff, UK
| | | | | |
Collapse
|
40
|
Zanca F, Jacobs A, Crijns W, De Wever W. Comparison of measured and estimated maximum skin doses during CT fluoroscopy lung biopsies. Med Phys 2015; 41:073901. [PMID: 24989420 DOI: 10.1118/1.4884231] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To measure patient-specific maximum skin dose (MSD) associated with CT fluoroscopy (CTF) lung biopsies and to compare measured MSD with the MSD estimated from phantom measurements, as well as with the CTDIvol of patient examinations. METHODS Data from 50 patients with lung lesions who underwent a CT fluoroscopy-guided biopsy were collected. The CT protocol consisted of a low-kilovoltage (80 kV) protocol used in combination with an algorithm for dose reduction to the radiology staff during the interventional procedure, HandCare (HC). MSD was assessed during each intervention using EBT2 gafchromic films positioned on patient skin. Lesion size, position, total fluoroscopy time, and patient-effective diameter were registered for each patient. Dose rates were also estimated at the surface of a normal-size anthropomorphic thorax phantom using a 10 cm pencil ionization chamber placed at every 30°, for a full rotation, with and without HC. Measured MSD was compared with MSD values estimated from the phantom measurements and with the cumulative CTDIvol of the procedure. RESULTS The median measured MSD was 141 mGy (range 38-410 mGy) while the median cumulative CTDIvol was 72 mGy (range 24-262 mGy). The ratio between the MSD estimated from phantom measurements and the measured MSD was 0.87 (range 0.12-4.1) on average. In 72% of cases the estimated MSD underestimated the measured MSD, while in 28% of the cases it overestimated it. The same trend was observed for the ratio of cumulative CTDIvol and measured MSD. No trend was observed as a function of patient size. CONCLUSIONS On average, estimated MSD from dose rate measurements on phantom as well as from CTDIvol of patient examinations underestimates the measured value of MSD. This can be attributed to deviations of the patient's body habitus from the standard phantom size and to patient positioning in the gantry during the procedure.
Collapse
Affiliation(s)
- F Zanca
- Department of Radiology, Leuven University Center of Medical Physics in Radiology, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium and Imaging and Pathology Department, UZ Leuven, Herestraat 49, Box 7003 3000 Leuven, Belgium
| | - A Jacobs
- Department of Radiology, Leuven University Center of Medical Physics in Radiology, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - W Crijns
- Department of Radiotherapy, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - W De Wever
- Imaging and Pathology Department, UZ Leuven, Herestraat 49, Box 7003 3000 Leuven, Belgium and Department of Radiology, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
| |
Collapse
|
41
|
Jacobs A, Rosumeck S. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis: comment. Clin Exp Dermatol 2015; 40:810-1. [PMID: 25703944 DOI: 10.1111/ced.12614] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/22/2014] [Indexed: 11/26/2022]
Affiliation(s)
- A Jacobs
- Division of Evidence Based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - S Rosumeck
- Division of Evidence Based Medicine, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
| |
Collapse
|
42
|
Kowar M, Frackowiak M, Friedrich C, Wilhelm K, Walger P, Jacobs A. Sensorische Aphasie unter Therapie mit Metronidazol – eine wichtige Differenzialdiagnose der akuten zerebralen Ischämie. Dtsch Med Wochenschr 2014; 139:2341-3. [DOI: 10.1055/s-0034-1387341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- M. Kowar
- Klinik für Geriatrie mit Neurologie und Tagesklinik
| | | | - C. Friedrich
- Klinik für Geriatrie mit Neurologie und Tagesklinik
| | | | - P. Walger
- Abteilung Innere Medizin, Intensivmedizin und Hygiene, Evangelische Kliniken, Johanniter Krankenhaus, Bonn
| | - A. Jacobs
- Klinik für Geriatrie mit Neurologie und Tagesklinik
| |
Collapse
|
43
|
Rubin S, Jacobs A. “The easiest way”: decision-making process of urban adolescents choosing to use an IUD. Contraception 2014. [DOI: 10.1016/j.contraception.2014.05.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
44
|
Nast A, Ernst H, Rosumeck S, Erdmann R, Jacobs A, Sporbeck B. Risk of complications due to anticoagulation during dermatosurgical procedures: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2014; 28:1603-9. [PMID: 25132203 DOI: 10.1111/jdv.12611] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Accepted: 05/26/2014] [Indexed: 01/22/2023]
Abstract
Background Management of anticoagulation and anti-platelet drugs during cutaneous surgery is still a challenge for many dermatologists and standards of care with respect to stopping, continuing or bridging vary widely. Methods We performed a systematic review (Medline, Cochrane Library, until August 27th, 2013) of studies assessing the risk of complications due to anticoagulation during cutaneous surgery. Primary outcomes were mild-moderate and severe postsurgical bleeding. The secondary outcomes were excessive and uncontrollable intraoperative bleeding and other postsurgical complications as wound dehiscence, erythema, wound infection. Results 1.287 publications were identified and 10 studies were included into the review. The frequencies of bleeding in the control groups in general were low (about 1%). In patients on aspirin, increased risks were seen neither with respect to mild-moderate postoperative bleeding (RR 1.1, CI 0.5-2.3), nor with respect to severe bleeding (RR 0.9, CI 0.2-4.6). The studies with patients on warfarin showed a risk for mild-moderate bleeding that was three times as high as in controls (RR 3.2, CI 1.4-7.1) and for severe bleeding that was 15 times higher (RR 14.8, CI 2.7-80.4). In general the study sizes were small and the methodological quality low. Conclusion The risk of bleeding due to a medication with aspirin seems to be negligible. With warfarin, the risk is increased; an exact estimate of the risk increase is difficult to give, because of the lack of sufficient high quality studies. A two-fold increase appears likely, the 15-fold increase is most likely due to statistical reasons arising from the rareness of the event in the small number of included patients. Stopping, bridging or continuing a medication should always be an individual decision. In accordance with guidelines from internal medicine for most patients it will be recommendable to continue with the medication.
Collapse
Affiliation(s)
- A Nast
- Division of Evidence-Based Medicine (dEBM), Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | | | | | | | | | | |
Collapse
|
45
|
Jacobs A, Schuler FM, Volpp HR, Wahl M, Wolfrum J. LIF-Measurements of the Dynamics of the Reactions HT(2.57 eV) + NO → OH + N and HT(1.86 eV) + O2→ OH + O. ACTA ACUST UNITED AC 2014. [DOI: 10.1002/bbpc.199000040] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
46
|
Jacobs A, Starke G, Rosumeck S, Nast A. Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris. Br J Dermatol 2014; 170:557-64. [DOI: 10.1111/bjd.12706] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2013] [Indexed: 11/30/2022]
Affiliation(s)
- A. Jacobs
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité-Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - G. Starke
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité-Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - S. Rosumeck
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité-Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| | - A. Nast
- Division of Evidence Based Medicine (dEBM); Department of Dermatology; Charité-Universitätsmedizin Berlin; Charitéplatz 1 10117 Berlin Germany
| |
Collapse
|
47
|
Bell D, Duffin A, Gruss HJ, Pediconi C, Jacobs A. A randomised, controlled, crossover study to investigate the pharmacodynamics, pharmacokinetics and safety of 1R,2S-methoxamine hydrochloride (NRL001) in healthy elderly subjects. Colorectal Dis 2014; 16 Suppl 1:27-35. [PMID: 24499494 DOI: 10.1111/codi.12543] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 12/29/2013] [Indexed: 12/17/2022]
Abstract
AIMS This study aimed to assess the effects of a single dose of 10 mg NRL001 (the 1R,2S stereoisomer of methoxamine hydrochloride) in a 2 g suppository on pharmacodynamic and pharmacokinetic (PK) variables, and safety, in a healthy elderly population. METHODS This was a Phase I, single-centre, randomised, double-blind, placebo-controlled crossover study during which subjects received a single 2 g suppository of 10 mg NRL001 and a matching placebo in two separate treatment periods. The main outcome measures were Holter-, vital signs- and electrocardiogram-derived cardiovascular variables; plasma PK analysis; and safety assessments. RESULTS Twenty-six subjects were dosed with study medication. Statistically significant reductions in Holter-derived heart rate (HR), vital signs-derived HR and diastolic blood pressure (BP) were observed comparing NRL001 with placebo treatment, and also with increasing NRL001 plasma concentration. No statistically significant relationships were observed between NRL001 concentration and systolic BP, mean arterial pressure or QTC interval (both Bazett's and Fridericia's correction). Thirty-nine adverse events were reported in 20 (76.9%) subjects, mostly after dosing with NRL001. CONCLUSION Administration of NRL001 suppositories led to decreases in HR when compared with placebo data. NRL001 was well tolerated with a good safety profile during the study. Healthy elderly subjects did not show significantly different biological responses to NRL001 suppositories compared with younger healthy volunteers in previous studies.
Collapse
Affiliation(s)
- D Bell
- BioKinetic Europe Limited, Belfast, UK
| | | | | | | | | |
Collapse
|
48
|
Gruss HJ, Pediconi C, Jacobs A. Meta-analysis for cardiovascular effects of NRL001 after rectal application in healthy volunteers. Colorectal Dis 2014; 16 Suppl 1:51-8. [PMID: 24499496 DOI: 10.1111/codi.12545] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 12/29/2013] [Indexed: 12/13/2022]
Abstract
AIMS NRL001 is a highly specific α1 -adrenoceptor agonist currently under evaluation for the treatment of faecal incontinence caused by a weak internal anal sphincter. The aim of this meta-analysis was to quantify the effect of NRL001 on cardiovascular parameters including heart rate, blood pressure and QT interval. METHODS Data from the four Phase I healthy volunteer studies SUM (NCT00857467), SURD (NCT01099670), SUSD (NCT00850590) and SAGE (NCT01099683) were pooled and analyses were performed on individual subject data. Mixed effects regression analysis was used to determine the effect of NRL001 on heart rate, blood pressure and QT intervals. A multivariate statistical model was used to determine the effect of covariates on heart rate. RESULTS Subjects given NRL001 experienced a dose related decrease in heart rate of up to 9.48 bpm compared with subjects in the placebo arms. No statistically significant evidence for a threshold effect was found. There was no clear evidence of dose effect of NRL001 on blood pressure. QT interval increased in all NRL001 subject as expected; QTC F also showed a statistically significant increase. However, QTC B was shortened with no significant treatment effect. CONCLUSIONS NRL001 was found to have a dose-dependent effect on heart rate; however clinically-relevant bradycardia was not reported, indicating the decrease in heart rate was not of clinical significance. Furthermore, no clinically-significant drug effect on blood pressure or mean arterial pressure was observed. QT intervals were affected by changes in heart rate. However, trends were dependant on the correction factor used. No consistent QT effect was observed, but a thorough QTC study will be required to confirm the effects of rectally applied NRL001.
Collapse
Affiliation(s)
- H J Gruss
- Medical & Safety Services, ICON Clinical Research, Eastleigh, UK
| | | | | |
Collapse
|
49
|
Bell D, Duffin A, Jacobs A, Pediconi C, Gruss HJ. A double-blind, placebo-controlled, randomised, parallel-group, dose-escalating, repeat dose study in healthy volunteers to evaluate the safety, tolerability, pharmacodynamic effects and pharmacokinetics of the once daily rectal application of NRL001 suppositories for 14 days. Colorectal Dis 2014; 16 Suppl 1:36-50. [PMID: 24499495 DOI: 10.1111/codi.12544] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 12/29/2013] [Indexed: 12/29/2022]
Abstract
AIMS The 1R,2S stereoisomer of methoxamine hydrochloride, NRL001, is a highly selective α1-adrenoceptor agonist being developed for the local treatment of non-structural faecal incontinence caused by weak internal anal sphincter tone. This study investigated the steady state pharmacokinetics (PK) and safety of 2 g rectal suppositories containing NRL001 in different strengths (7.5, 10, 12.5 or 15 mg). METHODS Healthy volunteers aged 18-45 years received 14 daily doses of NRL001 2 g suppositories or matching placebo. In each dose group nine participants received NRL001 and three received placebo. Blood samples to determine NRL001 concentrations were taken on Days 1, 7 and 14. Cardiovascular parameters were collected via electrocardiograms, Holter monitoring (three lead Holter monitor) and vital signs. RESULTS Forty-eight volunteers were enrolled; 43 completed the study and were included in the PK analysis population. AUC and Cmax broadly increased with increasing dose, Tmax generally occurred between 4.0 and 5.0 h. Although the data did not appear strongly dose proportional, dose proportionality analysis did not provide evidence against dose proportionality as the log(dose) coefficients were not significantly < 1. NRL001 did not accumulate over time for any dose. Increasing NRL001 concentrations were related to changes in vital sign variables, most notably decreased heart rate. The most commonly reported adverse events (AEs) in the active treatment groups were paraesthesia and piloerection. CONCLUSIONS Treatment with NRL001 was generally well tolerated over 14 days once daily dosing and plasma NRL001 did not accumulate over time. Treatment was associated with changes in vital sign variables, most notably decreased heart rate. AEs commonly reported with NRL001 treatment were events indicative of a systemic α-adrenergic effect.
Collapse
Affiliation(s)
- D Bell
- Bio-Kinetic Europe Limited, Belfast, UK
| | | | | | | | | |
Collapse
|
50
|
Simpson JAD, Bush D, Gruss HJ, Jacobs A, Pediconi C, Scholefield JH. A randomised, controlled, crossover study to investigate the safety and response of 1R,2S-methoxamine hydrochloride (NRL001) on anal function in healthy volunteers. Colorectal Dis 2014; 16 Suppl 1:5-15. [PMID: 24499492 DOI: 10.1111/codi.12541] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2013] [Accepted: 12/29/2013] [Indexed: 12/12/2022]
Abstract
AIMS This study aimed to assess the dose and volume effects of suppository preparations and safety of NRL001 (one of four possible stereoisomers of methoxamine hydrochloride) on anal sphincter tone using rectal suppositories in healthy adult volunteers. METHODS This was a Phase I, single-centre, randomised, double-blind, three-way crossover study during which subjects received three single doses of 1 g rectal suppositories (containing 5 or 10 mg NRL001 or matching placebo) or 2 g rectal suppositories (containing 10 or 15 mg NRL001 or matching placebo) on three separate dosing days. The outcome measures were mean anal resting pressure (MARP) variables (monitored continuously for 20-30 min before and up to 6 h after dosing), pharmacokinetics (PK) and safety assessments. RESULTS Twenty-six subjects were dosed with study medication. Two subjects were withdrawn prematurely and were not included in the main analysis. There was a dose-dependent increase in anal sphincter tone (MARP) when comparing the 5 and 10 mg doses of NRL001; however, the 15 mg dose did not have a significantly greater effect than the 10 mg dose. Suppository size (1 or 2 g) did not appear to have an effect on sphincter tone. There was no evidence against dose proportionality for the PK variables, but the mean maximum plasma concentration (Cmax ) for the 1 g suppository group was higher than for the 2 g group. Twenty-one adverse events were reported in 8 (30.8%) subjects. A dose dependent decrease in heart rate was noted; however, there were no adverse events reported that were related to this reduction in heart rate. CONCLUSIONS The increase in anal sphincter tone supports the potential therapeutic use of NRL001 in treating faecal incontinence, with further studies in patients required. NRL001 was well tolerated in single doses of up to 15 mg.
Collapse
Affiliation(s)
- J A D Simpson
- Division of Surgery, University of Nottingham, Nottingham, UK
| | | | | | | | | | | |
Collapse
|